334 related articles for article (PubMed ID: 17496428)
1. Bispecific antibodies: molecules that enable novel therapeutic strategies.
Fischer N; Léger O
Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
3. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
Shen J; Zhu Z
Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
[TBL] [Abstract][Full Text] [Related]
4. Diabodies: molecular engineering and therapeutic applications.
Wu C
Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
[TBL] [Abstract][Full Text] [Related]
5. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
6. Recombinant bispecific antibodies for cellular cancer immunotherapy.
Müller D; Kontermann RE
Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies for cancer therapy.
Chames P; Baty D
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
Kipriyanov SM; Le Gall F
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
[TBL] [Abstract][Full Text] [Related]
9. [Dual-specificity therapeutic antibodies].
Winckler T
Pharm Unserer Zeit; 2009; 38(5):395-6. PubMed ID: 19711313
[No Abstract] [Full Text] [Related]
10. Recombinant bispecific antibodies for cancer therapy.
Kontermann RE
Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies as novel bioconjugates.
Cao Y; Suresh MR
Bioconjug Chem; 1998; 9(6):635-44. PubMed ID: 9815155
[TBL] [Abstract][Full Text] [Related]
12. Bivalent monoclonal IgY antibody formats by conversion of recombinant antibody fragments.
Greunke K; Spillner E; Braren I; Seismann H; Kainz S; Hahn U; Grunwald T; Bredehorst R
J Biotechnol; 2006 Jul; 124(2):446-56. PubMed ID: 16490273
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
Siberil S; Dutertre CA; Boix C; Teillaud JL
Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
[TBL] [Abstract][Full Text] [Related]
14. Production of bispecific and trispecific F(ab)2 and F(ab)3 antibody derivatives.
French RR
Methods Mol Biol; 1998; 80():121-34. PubMed ID: 9664369
[No Abstract] [Full Text] [Related]
15. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
16. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
Niwa R; Satoh M
J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
[TBL] [Abstract][Full Text] [Related]
17. The assembly of single domain antibodies into bispecific decavalent molecules.
Stone E; Hirama T; Tanha J; Tong-Sevinc H; Li S; MacKenzie CR; Zhang J
J Immunol Methods; 2007 Jan; 318(1-2):88-94. PubMed ID: 17141798
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.
Wu C; Ying H; Grinnell C; Bryant S; Miller R; Clabbers A; Bose S; McCarthy D; Zhu RR; Santora L; Davis-Taber R; Kunes Y; Fung E; Schwartz A; Sakorafas P; Gu J; Tarcsa E; Murtaza A; Ghayur T
Nat Biotechnol; 2007 Nov; 25(11):1290-7. PubMed ID: 17934452
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
20. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
